ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data

Oric Pharmaceuticals, Inc.

Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.
R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).
ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.
Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).
Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.